+5.56% pre: 9G2.SI Singapore Institute of Advanced Medicine (SES) watch S$0.035

We see a pre-market surge in 9G2.SI stock after a high-volume session, with the price at S$0.038 and volume at 3,578,300.00 shares. The move marks a +5.56% change from yesterday’s close and puts the stock back above today’s low at S$0.035. As a high-volume mover on the SES in Singapore, 9G2.SI stock draws attention from short-term traders and event-driven funds. We outline the drivers, key levels, and a model forecast to frame a practical trading view for the pre-market session on 11 Mar 2026.

9G2.SI stock pre-market move and volume

9G2.SI stock opened at S$0.035 and traded up to S$0.038 in pre-market action, a +5.56% intraday rise on a 3,578,300.00 share print. This volume is large versus its average daily volume of 4,030,189.00, signalling genuine buyer interest rather than a thin uptick. The gap back toward the year low of S$0.026 keeps risk visible, but the spike confirms the stock is a top high-volume mover on SES today.

Fundamentals snapshot for Singapore Institute of Advanced Medicine (9G2.SI)

Singapore Institute of Advanced Medicine Holdings Ltd. (9G2.SI, SES) shows a market cap of S$35,560,607.00 and shares outstanding 1,045,900,200.00. Key ratios: EPS -0.02, PE -1.70, PB 0.84, and price-to-sales 2.23. The company reports negative earnings but modest book value per share at S$0.04056. These metrics indicate value-area interest but elevated operational stress, reflected in a debt-to-equity ratio of 1.77 and a current ratio of 0.27.

Technical picture and key price levels for 9G2.SI stock

The technicals show oversold momentum: RSI 21.40 and CCI -112.88. Short-term resistance sits near S$0.038 and the 50-day average at S$0.05476 offers a medium-term hurdle. Immediate support is S$0.035 and a break below that on rising volume would risk a retest of the year low at S$0.026. Traders should note on-balance volume (OBV 19,072,700.00) rising with price, supporting the legitimacy of the move.

Meyka AI grade, forecast and target for 9G2.SI

Meyka AI rates 9G2.SI with a score of 60.98 out of 100 — Grade B, HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of S$0.08606 versus the current S$0.038, implying a model upside of 126.46%. Forecasts are model-based projections and not guarantees.

Sector context and near-term catalysts for 9G2.SI stock

9G2.SI operates in the Healthcare sector, Medical – Care Facilities industry, where peers show higher liquidity and stronger margins. Sector performance is soft year-to-date, which raises sensitivity to company-level news. Watch for earnings updates, contract wins, and trading comparisons with competitors; recent aggregator coverage appears on investing.com comparing sector peers and activity Investing.com – Asia Vets compare and Investing.com – Cordlife compare.

Trading strategy and liquidity notes for high-volume traders

Given the pre-market volume surge, short-term traders should size positions to account for wide intraday swings and low free-float liquidity. Use tight stop-losses near S$0.035 and scale out at S$0.05476 (50-day average) and S$0.089 (year high) if momentum holds. We link the market page for live quotes and order-book context on Meyka: Meyka stock page 9G2.SI.

Final Thoughts

9G2.SI stock is a clear high-volume mover in the pre-market session on 11 Mar 2026, trading at S$0.038 on 3,578,300.00 shares and a +5.56% jump from the prior close. Short-term traders can treat S$0.035 as the immediate support and S$0.05476 as the first disciplined target. Meyka AI’s forecast model projects a yearly price of S$0.08606, implying an upside of 126.46% from the current level; forecasts are model-based projections and not guarantees. Balance the strong short-term momentum against weak fundamentals, including negative EPS and a low current ratio, and position sizing should reflect the stock’s volatility and liquidity constraints. We use Meyka AI as an AI-powered market analysis platform to combine technical triggers with model forecasts, but this is informational only and not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.